Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd

HKPD
Cellyan Biotechnology Co., LtdUS flagNASDAQ Capital Market
0.52
USD
+0.00
- -
5.71MMarket Cap
2023 Y
2024 Y
2025 Y
Revenue per Share
1.14
1.52
1.99
Basic EPS, GAAP
0.09
0.12
- -
Free Cash Flow per Basic Share
0.15
-0.04
0.04
Dividend per Share
- -
- -
- -
Book Value per Share
0.02
0.14
0.15
Tangible Book Value per Share
0.05
0.38
0.48
Basic Weighted Avg Shares
11
11
10
Sales/Revenue/Turnover
13
17
20
Operating Margin (%)
8.58
10.03
0.99
Depreciation Expense
1
1
1
Net Income, GAAP
1
1
- -
Effective Tax Rate (%)
2.21
12.86
174.92
Profit Margin (%)
7.95
7.97
-0.13
Working Capital
- -
5
6
LT Debt
- -
1
2
Total Equity
1
4
5
Return on Invested Capital (%)
- -
37.11
-2.14
Return on Capital (%)
- -
61.93
-2.67
Return on Common Equity (%)
- -
152.02
-1.77

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
17.31%
Free Cash Flow
- -
- -
-185.88%
Net Income, GAAP
- -
- -
-102.03%
Sales/Revenue/Turnover
- -
- -
21.72%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
17
2025
- -
- -
- -
- -
20
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.12
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Chenyu Liang
Full Time Employees
27
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
Well Town Industrial Building Yau Tong Hong Kong 999077
IPO Date
Jan 15, 2025
Website
9zt.hk
Business
Hong Kong Pharma Digital Technology Holdings Limited, an investment holding company incorporated in the Cayman Islands in 2023 with operational roots established in 2016, serves as a leading provider of over-the-counter (OTC) pharmaceutical cross-border e-commerce supply chain services and procurement and distribution solutions, primarily operating through its Hong Kong subsidiaries Joint Cross Border and V-Alliance; the company delivers comprehensive one-stop services including OTC product wholesale, GSP-certified multi-temperature warehousing, pharmaceutical logistics and transportation, import/export customs clearance, drug enlisting with the Hong Kong Department of Health, packaging, supply chain analysis and optimization, real-time temperature monitoring, and end-to-end delivery for merchants, e-commerce platform logistics partners, pharmaceutical distributors, and consumers in Hong Kong and Mainland China. Headquartered at Room B1, 5/F, Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon, Hong Kong, the company facilitates the transport of medicines from global sources to Hong Kong storage facilities and onward cross-border transfers to Mainland China via e-commerce channels, maintaining certifications such as GSP qualification, Hong Kong government approvals, ISO quality management, and vehicle compliance. In recent developments, Hong Kong Pharma Digital Technology Holdings Limited completed its initial public offering on the NASDAQ under ticker HKPD in January 2025, raising $6.0 million by pricing 1.5 million shares at $4.00, followed by ringing the Opening Bell; in February 2025, it formed a strategic partnership with a leading technology-driven Chinese e-commerce platform to enhance cross-border logistics, order fulfillment, and warehouse management services; additionally, the company announced its 2025 Equity Incentive Plan and scheduled its annual general meeting for December 12, 2025.

Company News

APIChat
  • Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency

  • Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders

  • Hong Kong Pharma Digital Technology (NASDAQ:HKPD) Stock Price Up 0.3% – Here’s What Happened

  • DCS Announces Q3 2025 Quarterly Financial Statements

  • Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024

  • U.S. IPO Weekly Recap: Oil And Gas Well Equipment Provider Flowco Debuts, While More Sizable Deals Join The Pipeline

  • Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering